Prostate Cancer Report
ESMO 2019

The Prostate Cancer market will be impacted by nmCRPC¹, mCSPC² and mCRPC³ data presented during the European Society for Medical Oncology (ESMO) meeting in Barcelona, Spain.

Breaking Data will be working with 30 oncologists during the meeting to better understand the commercial implications of data presented for ERLEADA^® (apalutamide), JETVANA^® (cabazitaxel), TAXOTERE^® (docetaxel), XTANDI^® (enzalutamide), ZEJULA^® (niraparib), LYNPARZA^® (olaparib), and RUBRACA^® (rucaparib).

Companies presenting data include: AstraZeneca, Clovis, Janssen, Pfizer, Sanofi-Genzyme.

Get immediate access to this 65-slide report so you can make better decisions today and prepare for tomorrow.